

## United States Patent and Trademark Office



APPLICATION N	0.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/038,117	·	12/31/2001	Dilip Wagle	361331-513	5389
25561	7590	10/08/2003		EXAMINER	
ALLEN	BLOOM	И	BAHAR, MOJDEH		
C/O DEC		E CORPORATION	ART UNIT	PAPER NUMBER	
P.O. BOX	5218		1617	Ø	
PRINCET	ON, N	08543-5218	DATE MAILED: 10/08/2003	0	

Please find below and/or attached an Office communication concerning this application or proceeding.

<i>"</i>		انت	•					
		Application No.	Applicant(s)					
•		10/038,117	WAGLE ET AL.					
	Office Action Summary	Examiner	Art Unit					
		Mojdeh Bahar	1617					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1)🖂	Responsive to communication(s) filed on 6	<u> 2 July 2003</u> .						
2a)□	This action is <b>FINAL</b> . 2b)⊠	This action is non-final.						
3)	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
, –	4) Claim(s) 1-10 is/are pending in the application.							
4a) Of the above claim(s) <u>6 and 8-10</u> is/are withdrawn from consideration.								
_	5) Claim(s) is/are allowed.							
	6)⊠ Claim(s) <u>1-5 and 7</u> is/are rejected.							
	7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) 🗆 -	11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13)	Acknowledgment is made of a claim for fore	eign priority under 35 U.S.C. § 119(	a)-(d) or (f).					
a)[	☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority docume	ents have been received.						
	2. Certified copies of the priority docume	ents have been received in Applica	tion No					
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)					
U.S. Patent and Tr PTO-326 (Re		Action Summary	Part of Paper No. 8					

Application/Control Number: 10/038,117

Art Unit: 1617

## **DETAILED ACTION**

Applicant's election of Het as a five-membered ring containing one Nitrogen and one Oxygen and Y as Hydrogen, and hypertension as the disorder is acknowledged.

The search of the elected compound specie of isoxazole has been expanded to include the compounds encompassed by Yanaka et al. (US 5,932,575).

Claims 6 and 8-10 are withdrawn from consideration as being drawn to non-elected species. Claims 1-5 and 7 are herein examined on the merits in so far as they read on the elected specie of isoxazole and the formula I compounds encompassed by Yanaka et al. (US 5,932,575).

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-5 and 7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Base claim 1 recites a "method of treating or ameliorating an indication of an invention". This recitation is not clear. What is "an indication of the invention"? How is "an indication of the invention" defined? What is "the invention" set forth in this claim? Note that this phrase is vague and indefinite. Due to this indefiniteness the metes and bounds of the claims cannot be ascertained by the Skilled Artisan.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Application/Control Number: 10/038,117

Art Unit: 1617

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5 and 7 are rejected under 35 U.S.C. 102(b) as being anticipated by Yanaka et al. (US 5,932,575).

Yanaka et al. (US 5,932,575) teaches a method of treating cardiac diseases such as hypertensive cardiac diseases comprising administering to the patient a compound of formula I (which encompasses some of the compounds encompassed by formula I of the instant application) or pharmacologically acceptable salts thereof, see claims 1-9 and col. 6, lines 12-26 in particular.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-1007. The examiner can normally be reached on (703) 305-1007 from Monday to Friday from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar Patent Examiner October 2, 2003

> SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER

> > 10/3/23